Lantheus Holdings, Inc. (LNTH) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US5165441032
Lantheus Holdings, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 1.54 bn USD |
| Gross profit | 941.95 m USD |
| Operating income | 310.83 m USD |
| EBIT | 333.54 m USD |
| Net income | 233.56 m USD |
| Diluted EPS – continuing operations | 3.41 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
More stocks
- BlueFocus Communication Group (300058.SZ)
- Korea Investment Holdings Co (071050.KS)
- Sandfire Resources Ltd (SFR.AX)
- Tokio Marine Holdings Inc (8766.T)
- Rakuten Bank Ltd (5838.T)
- Companhia Energetica de Minas Gerais CEMIG Pref ADR (CIG)
- OR Royalties Inc (OR.TO)
- Akr Corporindo Tbk (AKRA.JK)
- Amdocs Ltd (DOX)
- ESCO TECHNOLOGIES INC (ESE)
- Artemis Gold Inc (ARTG.V)
- China Reinsurance (Group) Corp (1508.HK)
Not investment advice. All data without warranty, price as of 19.10.2026. Details in the risk notice.